Traina TA, et al. - Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. In this phase II study, researchers assessed the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC. Clinical activity, as well as good tolerability of enzalutamide, was apparent in patients with advanced AR-positive TNBC. Furthermore, enzalutamide-associated adverse events were found to be consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC.